Spiderwort is developing a novel biomaterial that will offer new avenues in regenerative medicine. We are using plant derived cellulose to create a variety of scaffold architectures. Currently, we are in the pre-clinical stage of this product and our promising results demonstrate that this new biomaterial is highly biocompatible and induceangiogenesis (blood vessel generation inside the scaffold).

Health Care

Biotechnology

Spiderwort Inc.

Charles M. Cuerrier

Stephen Hanson

Scott Jarvis, Virtual CFO

Michelle Masson

Andrew Pelling

The Research and Development team at Spiderwort Inc. is dedicated to pioneering the application of plant-derived cellulose in regenerative medicine. Focusing on innovative scaffold architectures, the team conducts rigorous pre-clinical research to assess the biocompatibility and angiogenic properties of their novel biomaterials. Their collaborative efforts aim to translate scientific discoveries into viable therapeutic solutions for tissue regeneration.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Spiderwort Inc.

Leadership Team